ST Segment Elevation Myocardial Infarction Clinical Trial
Official title:
The Effect of Ischemic Postconditioning in Patients With STEMI Undergoing Primary PCI (DANAMI4-iPOST2)
In a prospective, randomized clinical trial the iPOST2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for STEMI patients who present with TIMI0-1 undergoing primary PCI
Myocardial reperfusion with the use primary percutaneous coronary intervention (PCI) is effective, but restoration of blood flow may itself jeopardize the myocardium, a phenomenon known as reperfusion injury. In ischemic postconditioning (iPOST), repetitive interruptions of blood flow to the injured region applied after initial reperfusion, has been shown favorable with different modalities such as biomarkers, echocardiography and cardiac magnetic resonance. However, the largest trial to date (DANAMI3-iPOST) failed to show clinical favor of iPOST when compared to conventional PCI. Importantly, however, in DANAMI3-iPOST thrombectomy was allowed and this might have impaired postconditioning, since thrombectomy itself creates reperfusion and thus reperfusion damage. Analysis of the fraction of DANAMI3-iPOST patients not undergoing thrombectomy showed a remarkable 45% reduction in death and heart failure in favor of postconditioning. iPOST2 will investigate in a randomized, prospective and adequately powered trial the effect of iPOST without thrombectomy compared to conventional PCI on the development of heart failure and death in STEMI patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02869906 -
Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction
|
N/A | |
Not yet recruiting |
NCT03895983 -
ST Segment Resolution After Primary Percutaneous Coronary Intervention.
|
||
Not yet recruiting |
NCT03252665 -
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI
|
Phase 4 | |
Completed |
NCT02026219 -
Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction
|
Phase 4 | |
Completed |
NCT03247738 -
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
|
Phase 4 | |
Recruiting |
NCT05461781 -
Distal Transradial Access for Primary PCI in STEMI Patients to Prevent RAO
|
N/A | |
Recruiting |
NCT03561389 -
iFR-guided Revascularization in STEMI
|
||
Completed |
NCT01538303 -
Microvascular Dysfunction in Acute Myocardial Infarction (AMI) and Its Relation to Outcome
|
||
Recruiting |
NCT02979236 -
Italian Multi-center Registry of Self-apposing Coronary Stent in Patients With STEMI
|
N/A | |
Completed |
NCT05705089 -
Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI
|
Phase 3 | |
Completed |
NCT01897350 -
Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial
|
N/A | |
Not yet recruiting |
NCT03753269 -
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
|
Phase 4 | |
Completed |
NCT03234348 -
MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction
|
Phase 3 | |
Recruiting |
NCT03406832 -
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
|
N/A | |
Recruiting |
NCT03406819 -
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
|
N/A | |
Recruiting |
NCT03508232 -
Doxycycline to Protect Heart Muscle After Heart Attacks
|
Phase 2 | |
Recruiting |
NCT04220736 -
Early Prediction of QFR in STEMI-Pharmaco-invasice
|
||
Completed |
NCT03780335 -
Early Prediction of QFR in STEMI-I
|
||
Recruiting |
NCT03621111 -
A Trial on the Role of Community Pharmacist in Improving Adherence and Clinical Outcomes in Post-Infarction
|
N/A | |
Recruiting |
NCT03764241 -
Treatment of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant
|
Phase 3 |